Cost-effectiveness analysis of neurocognitive-sparing treatments for brain metastases

Cancer

Volumn 121, Issue 23, 2015, Pages 4231-4239

  Savitz, Samuel T ^a   Chen, Ronald C ^b,c   Sher, David J ^d  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

cognition disorders; computer assisted radiotherapy; cost effectiveness analysis; image guided radiotherapy; secondary brain neoplasm

Indexed keywords

ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIOTHERAPY; INTERMETHOD COMPARISON; MEDICARE; PRIORITY JOURNAL; PROBABILITY; SALVAGE THERAPY; SENSITIVITY ANALYSIS; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME; WHOLE BRAIN RADIOTHERAPY; AGED; BRAIN NEOPLASMS; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; HIPPOCAMPUS; HUMAN; MARKOV CHAIN; RADIATION RESPONSE; RADIOSURGERY; SECONDARY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WHOLE BODY RADIATION;

AGED; BRAIN NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; HIPPOCAMPUS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; RADIOSURGERY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 84948572014     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29642     Document Type: Article

References (27)

1. Wen PY, Loeffler JS. Brain metastases. Curr Treat Options Oncol. 2000;1:447-458.
2. Gondi V, Tome WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. Radiother Oncol. 2010;97:370-376.
3. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483-2491.
4. Gondi V, Pugh SL, Tom-e WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32: 3810-3816.
5. Bradley KA, Mehta MP. Management of brain metastases. Semin Oncol. 2004;31:693-701.
6. Mehta M, Vogelbaum MA, Chang S, Patel N. Neoplasms of the central nervous system. In: DeVita Jr. V.T., Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Wolters Kluwer/Lippincott Williams & Wilkins; 2011: 1700-1749.
7. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with 1 to 3 brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665-1672.
8. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037-1044.
9. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1 to 3 cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134-141.
10. Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases [serial online]. Cochrane Database Syst Rev. 2012;4:CD003869.
11. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-Dhe curious resilience of the 50, 000-per-QALY threshold. N Engl J Med. 2014;371:796-797.
12. Patil CG, Pricola K, Sarmiento JM, Garg SK, Bryant A, Black KL. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases [serial online]. Cochrane Database Syst Rev. 2012;9:CD006121.
13. Centers for Medicare & Medicaid Services. Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Hospital Value-Based Purchasing Program; Organ Procurement Organizations; Quality Improvement Organizations; Electronic Health Records (EHR) Incentive Program; Provider Reimbursement Determinations and Appeals. Fed Reg. 2013;78(pt 3);1-376.
14. Centers for Medicare & Medicaid Services. Physician Fee Schedule. 2014. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/index.html?redirect=/Physici anFeeSched/01-Overview.asp. Accessed July 19, 2014.
15. Centers for Medicare & Medicaid Services. FY 2014 Wage Index Home Page. 2014. Available at: http://www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY-2014-Wage-Index-Home-Page.html. Accessed July 19, 2014.
16. Medicare Learning Network. Hospital Outpatient Prospective Payment System. Baltimore, Md: Centers for Medicare & Medicaid Services; 2014.
17. Crawford M, Church J. CPI Detailed Report Data for June 2014. Washington, DC: Bureau of Labor Statistics; 2014.
18. Arias E. United States life tables, 2010. Natl Vital Stat Rep. 2014; 62:1-63.
19. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427-434.
20. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11:iii-iv, ix-221.
21. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1-202, iii-iv.
22. Oremus M, Tarride JE, Clayton N, Canadian Willingness-Do-Pay Study Group, Raina P. Health utility scores in Alzheimer's disease: differences based on calculation with American and Canadian preference weights. Value Health. 2014;17:77-83.
23. Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2:210-225.
24. The Boards of Trustees, Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. Communication: 2013 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. Baltimore, Md: Centers for Medicare & Medicaid Services; 2013.
25. Brown PD, Asher AL, Ballman KJ, et al. NCCTG N0574 (Alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases [abstract]. J Clin Oncol. 2015;33(18 suppl). Abstract LBA4.
26. Lal LS, Byfield SD, Chang EL, et al. cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery and whole brain radiation therapy in patients with 1 to 3 brain metastases. Am J Clin Oncol. 2012;35:45-50.
27. American Board of Internal Medicine Foundation. ASTRO releases second list of 5 radiation oncology treatments to question, as part of national Choosing WiselyVR campaign. 2014. Available at: http://www.choosingwisely.org/astro-releases-second-list/. Accessed May 9, 2015.